Sentence examples for basis of preclinical models from inspiring English sources
On the basis of preclinical models, we hypothesized pharmacodynamic separation, achieved by intermittent delivery of epidermal growth factor receptor tyrosine kinase inhibitors intercalated with chemotherapy, as a reasonable strategy to deliver combination therapy.
We posit that this knowledge lays the basis for identifying bona fide molecular targets and developing solid therapeutic approaches, requiring accurate patient selection and taking advantage of preclinical models to assist clinical development of novel combination strategies.
The role of preclinical models in cancer drug development continues to evolve.
This concept of anti-inflammatory therapy of sepsis was developed on the basis of the preclinical models of endotoxin-induced septic shock – models that are obviously not predictive for the immunopathology of sepsis in the majority of critically ill patients.
On the basis of our preclinical model, we expected ∼25% of the samples we received to be positive for the LRRC19/IGFBP2 biomarker; however, of the 16 samples analyzed for this biomarker, none tested positive.
Translational PK and PK-PD models developed on the basis of preclinical data on CNS active drugs is a promising approach to improve prediction of CNS target site concentrations in human and associated effects.
Rapamycin administered intraperitoneally at 5 mg/kg was used previously in a genetically engineered MPNST mouse model (Johannessen et al, 2008), and the sorafenib dose was chosen on the basis of preclinical studies in which daily oral administration of Sorafenib at 30 60 mg/kg was tested in several tumor models (Wilhelm et al, 2004).
Phase I trials have also been conducted on the basis of preclinical studies that demonstrated promising antitumor activity with acceptable safety results in human B-cell lymphoma models.
On the basis of preclinical results necrosis is likely to be the physiological factor underlying this association [ 75, 76].
However, no gender differences in the safety, tolerability as well as efficacy are expected on the basis of preclinical findings.
In addition, heat shock protein (HSP) 90 inhibitors are suggested as therapeutic options to overcome resistance on the basis of anti-tumor activity in preclinical models of ALK-driven lung cancer [ 11, 12] and small-scale clinical trials on ALK-positive lung cancers [ 13].
